Award
NIH Reporter #PAR-19-327
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
Recipient
Not Specified
Award Amount
$1,597,923.00
Ceiling
$1,597,923.00
Awarded
September 01, 2022
Identifier
PAR-19-327
NIH/NIDA awarded a clinical trial project to study transdermal rotigotine as an adjunct to behavioral therapy for Cocaine Use Disorder, with an award amount of about $1.6 million for the period 2022-2026.
Description
This project involves a clinical trial of transdermal rotigotine as an adjunct to behavioral therapy for Cocaine Use Disorder, with a focus on improving cocaine abstinence and executive function. The project is funded by NIH/NIDA under grant PAR-19-327, with a total award amount of approximately $1.6 million. The project duration is from September 2022 to September 2026.